U.S. markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
280.21-1.50 (-0.53%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close281.71
Bid280.21 x 900
Ask285.00 x 800
Day's Range276.03 - 282.08
52 Week Range223.25 - 363.92
Avg. Volume1,097,758
Market Cap42.187B
Beta (5Y Monthly)0.42
PE Ratio (TTM)14.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-29% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate

    Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate

    Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)

  • Biogen's Retinal Disease Gene Therapy Flunks Mid-Stage Study

    Biogen's Retinal Disease Gene Therapy Flunks Mid-Stage Study

    View more earnings on BIIBSee more from BenzingaClick here for options trades from BenzingaBiogen Buys Acute Ischemic Stroke Candidate For One-Time Payment Of MBiogen, Capsigen Ink .3B AAV Capsids Development Pact For CNS & Neuromuscular Disorders© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Reuters

    UPDATE 1-Biogen's experimental eye treatment fails to meet study goal

    Biogen Inc's experimental gene therapy for a genetic retinal disease that leads to progressive vision loss did not meet the main goal of a mid-to-late stage study, the drugmaker said on Friday. The treatment, BIIB112, did not show significant improvement in retinal sensitivity in patients with X-linked retinitis pigmentosa, a rare eye condition that has no approved treatments. The drug, however, showed positive trends in improving visual acuity under low light conditions and Biogen is analyzing the complete data from the study to figure out next steps.